Cellectis S.A. (NASDAQ:CLLS) Sees Large Increase in Short Interest

by · The Markets Daily

Cellectis S.A. (NASDAQ:CLLS – Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 203,500 shares, an increase of 59.7% from the December 15th total of 127,400 shares. Based on an average daily volume of 108,400 shares, the short-interest ratio is currently 1.9 days.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently modified their holdings of CLLS. XTX Topco Ltd acquired a new stake in Cellectis during the second quarter valued at $29,000. Long Focus Capital Management LLC raised its stake in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Finally, First Affirmative Financial Network acquired a new stake in shares of Cellectis during the 3rd quarter valued at about $45,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on CLLS shares. Barclays dropped their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. StockNews.com began coverage on Cellectis in a report on Thursday. They issued a “sell” rating on the stock.

Check Out Our Latest Report on Cellectis

Cellectis Stock Down 1.3 %

NASDAQ:CLLS traded down $0.02 on Friday, hitting $1.49. 202,767 shares of the company’s stock traded hands, compared to its average volume of 274,565. The company has a market cap of $82.81 million, a PE ratio of -1.14 and a beta of 3.08. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average price of $1.84 and a 200-day moving average price of $2.00.

Cellectis (NASDAQ:CLLS – Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the previous year, the firm posted ($0.31) earnings per share. Equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Read More